The Effects Of Pioglitazone And MK886 ON THE Mrna EXPRESSION OF PPAR-alpha, PPAR-gamma And Its Associated GENES, Cell Death And Migration In MDA-MB- 231 Cancer Cells
Pioglitazone (PGZ) is a prescription drug used in the treatment of diabetes mellitus type II. It is a well-known synthetic agonist for PP AR, and being studied extensively by our research group as a target drug for the treatment of ER-negative breast cancer. The ER-negative breast cancer is more...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2015
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/56796/1/00001792017%20Kalpanah%20a.p%20Nadarajan.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Pioglitazone (PGZ) is a prescription drug used in the treatment of diabetes mellitus
type II. It is a well-known synthetic agonist for PP AR, and being studied extensively
by our research group as a target drug for the treatment of ER-negative breast cancer.
The ER-negative breast cancer is more aggressive and fast growing than the ERpositive
breast cancer. Moreover, this type of cancer has a poor prognosis generally
and is often unresponsive to anti-estrogen therapy. A preliminary research showed
that treatment of MDA-MB-231 with PGZ produced little effect on cell growth and
did not induce apoptosis in the cancer cells despite increasing the levels of PPARa
mRNA expression in the cells. As such, to further evaluate the role of the PPARa
mRNA expression in MDA-MB-231, the effects of paz and MK886 on the
induction and inhibition of inRNA expression of PPARa, respectively, and other
associated genes in MDA:.MB-231 were determined in this study. The biological
mechanisms induced by both drugs were also assessed in this study. To achieve all
objectives of the study, the mRNA expression levels of PPARa in PGZ-treated and
MK886-treated MDA-MB-231 were determined using Real-Time PCR; the growth
inhibitory effects of PGZ and MK886 in MDA-MB-231 were determined using the
Trypan Blue Exclusion Assay and Real-time PCR; the apoptosis induction by PGZ
and MK886 in MDA-MB-231 was determined using the DNA Fragmentation Assay, Real-Time PCR, cell staining and Flow Cytometry, and the migration of PGZ-treated
and MK886-treated MDA-MB-231 was determined using the Wound Healing Assay. |
|---|